Dr Reddy stock: Dr Reddy sets October 23 results. P/ E is 31.29 for Dr Reddy stock

Published on 10/19/2026 at 15:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-quarter revenue fell 5.60 percent to INR 80.71 billion year over year. Dr Reddy stock costs INR 1,242.50 on October 19, 2026 at 3:29 p.m. IST, up 0.77 percent versus the prior close.

Results and valuation

Dr Reddy will announce results for the quarter and six months ended September 30, 2026, on October 23, 2026.
First-quarter revenue fell 5.60 percent year over year to INR 80.71 billion.
Dr Reddy stock was last at INR 1,242.50 on October 19, 2026 at 3:29 p.m. IST, up 0.77 percent versus the prior close.
Dr Reddy traded at a P/E ratio of 31.29 on October 19, 2026.

Dr Reddy stock, pharmaceuticals, quarterly results, valuation, NSE, Nifty 50, Illustration mit AI erstellt.

Dr Reddy will announce results for the quarter and six months ended September 30, 2026, on October 23, 2026, after its board meeting, according to StockTitan. Dr Reddy stock was last at INR 1,242.50 on October 19, 2026 at 3:29 p.m. IST, up 0.77 percent versus the prior close.

First-quarter revenue comparison

Revenue reached INR 80.71 billion in the first quarter of fiscal 2027, down 5.60 percent from the year-ago quarter. Consolidated net income was INR 4.44 billion for the same period, while operating cash flow was minus INR 0.93 billion.

Business Insider reported that the first-quarter result was affected by inventory and related costs linked to semaglutide supply disruptions. The comparison matters because the October 23 release will cover both the September quarter and the first half of fiscal 2027.

Price range and turnover

The NSE quote stood between its 52-week low of INR 1,101.00 and high of INR 1,414.90 on October 19, 2026. The current price was 12.19 percent below the high and 12.85 percent above the low, while volume reached 1,023,834 shares against an average of 1,912,709.

The stock's daily gain of 0.77 percent was smaller than the move in the prior session's quoted range. The price therefore remained within its established annual band rather than testing either boundary.

Valuation and reporting calendar

Dr Reddy had a market capitalization of INR 1.0 trillion, a P/E ratio of 31.29 and a dividend yield of 0.01 percent on October 19, 2026. The October 23 reporting date is the next scheduled company event identified by StockTitan.

The company is expected to discuss results for the quarter and six months ended September 30, 2026 during its earnings call on October 23, 2026 at 7:30 p.m. IST. That schedule gives investors a defined date for assessing whether the first-quarter revenue decline and semaglutide-related costs persisted.

Comparison with peers

Dr Reddy (NSE, INR): plus 0.77 percent, P/E 31.29, market capitalization INR 1.0 trillion

Sun Pharmaceutical Industries (NSE, INR): minus 0.90 percent, P/E 34.58, market capitalization INR 4.2 trillion

Cipla (NSE, INR): minus 0.08 percent, P/E 31.75, market capitalization INR 1.1 trillion

Stock position

Dr Reddy's valuation was close to Cipla's on October 19, 2026, while Sun Pharmaceutical Industries carried the higher P/E ratio. The upcoming results will provide the next reported comparison for revenue, profitability and cash generation.